• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

设计获取遗传资源的监管框架:一种多利益相关方多标准方法。

Designing Regulatory Frameworks for Access to Genetic Resources: A Multi-Stakeholder Multi-Criteria Approach.

作者信息

Sirakaya Aysegul, De Brucker Klaas, Vanagt Thomas

机构信息

Faculty of Law, Department of European, Public and International Law, UGent - Ghent University, Ghent, Belgium.

ABSint - Access and Benefit-Sharing International, Bruges, Belgium.

出版信息

Front Genet. 2020 Dec 3;11:549836. doi: 10.3389/fgene.2020.549836. eCollection 2020.

DOI:10.3389/fgene.2020.549836
PMID:33343618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7745761/
Abstract

In this paper we conduct a multi-criteria analysis (MCA) from a multiple stakeholder point of view for the design of access and benefit sharing (ABS) agreements concerning genetic resources, in particular regarding the access component of such agreements. We start by analyzing the objectives defined by international law (viz. the Convention on Biodiversity and the Nagoya Protocol) that every party (i.e., all United Nations member states, except the United States) must strive to attain when developing national legislation on ABS. As countries have a certain degree of freedom concerning the way and the extent to which they need to integrate these objectives into their national frameworks and since stakeholders attach different levels of importance to these objectives, such an MCA will help identify those options that command the highest value added from the community of stakeholders. Consequently, those options are expected to hold the highest potential for successful implementation. The MCA performed in this paper is based on Saaty's analytic hierarchy process (AHP) and starts from the objectives (i.e., criteria) enshrined in international law, and then proceeds by assessing the relative importance of these criteria from the point of view of four different stakeholder groups (industrial users, academic users, collections and provider countries). The alternatives to be evaluated in the MCA are based upon options discussed qualitatively in our previous study published in (2019b). These options are now transformed into "design parameters" and are evaluated in terms of their contribution to stakeholder criteria. This evaluation is now performed in a quantitative way using MCA and is based on previous qualitative discussions with stakeholders that have been reported qualitatively in our previous paper in referred to above. The final result of our MCA consists of pointing out which design parameters regarding access obtain the highest priority from the community of stakeholders and hence need to be present in national regulatory frameworks on ABS that will be implemented by member states. It is our intention to undertake similar research for the Benefit Sharing component of ABS agreements in the future.

摘要

在本文中,我们从多个利益相关者的角度进行多标准分析(MCA),以设计关于遗传资源的获取与惠益分享(ABS)协议,特别是此类协议的获取部分。我们首先分析国际法(即《生物多样性公约》和《名古屋议定书》)所界定的目标,每个缔约方(即除美国外的所有联合国会员国)在制定关于ABS的国家立法时都必须努力实现这些目标。由于各国在将这些目标纳入其国家框架的方式和程度上有一定的自由度,而且利益相关者对这些目标的重视程度各不相同,这样的多标准分析将有助于确定那些从利益相关者群体中获得最高附加值的选项。因此,预计这些选项具有最高的成功实施潜力。本文所进行的多标准分析基于萨蒂的层次分析法(AHP),从国际法所规定的目标(即标准)出发,然后从四个不同的利益相关者群体(工业用户、学术用户、收藏机构和提供国)的角度评估这些标准的相对重要性。多标准分析中要评估的备选方案基于我们在2019年发表的上一项研究中定性讨论的选项。这些选项现在被转化为“设计参数”,并根据它们对利益相关者标准的贡献进行评估。现在使用多标准分析以定量方式进行这种评估,并且基于我们在上述上一篇论文中定性报告的与利益相关者的先前定性讨论。我们多标准分析的最终结果是指出哪些关于获取的设计参数从利益相关者群体中获得最高优先级,因此需要纳入会员国将实施的关于ABS的国家监管框架中。我们打算未来对ABS协议的惠益分享部分进行类似的研究。

相似文献

1
Designing Regulatory Frameworks for Access to Genetic Resources: A Multi-Stakeholder Multi-Criteria Approach.设计获取遗传资源的监管框架:一种多利益相关方多标准方法。
Front Genet. 2020 Dec 3;11:549836. doi: 10.3389/fgene.2020.549836. eCollection 2020.
2
Balanced Options for Access and Benefit-Sharing: Stakeholder Insights on Provider Country Legislation.获取与惠益分享的平衡选项:利益相关者对提供国立法的见解
Front Plant Sci. 2019 Oct 1;10:1175. doi: 10.3389/fpls.2019.01175. eCollection 2019.
3
Explanation of the Nagoya Protocol on Access and Benefit Sharing and its implication for microbiology.《名古屋遗传资源获取与惠益分享议定书》解读及其对微生物学的影响
Microbiology (Reading). 2017 Mar;163(3):289-296. doi: 10.1099/mic.0.000425. Epub 2017 Mar 29.
4
Access and Benefit Sharing Under the Nagoya Protocol-? Six Latin American Case Studies Assessing Opportunities and Risk.《名古屋议定书》下的获取与惠益分享——六个拉丁美洲案例研究:评估机遇与风险
Front Pharmacol. 2020 Jun 8;11:765. doi: 10.3389/fphar.2020.00765. eCollection 2020.
5
Genebank Operation in the Arena of Access and Benefit-Sharing Policies.获取与惠益分享政策领域中的基因库运作
Front Plant Sci. 2020 Jan 22;10:1712. doi: 10.3389/fpls.2019.01712. eCollection 2019.
6
Implementation of the Nagoya Protocol in the European Union and in Germany.《在欧盟和德国实施<名古屋议定书>》。
Phytomedicine. 2019 Feb;53:313-318. doi: 10.1016/j.phymed.2018.10.020. Epub 2018 Oct 26.
7
Governing synthetic biology in the light of the Access and Benefit Sharing regulation (ABS).根据《获取与惠益分享条例》(ABS)对合成生物学进行管理。
Rev Derecho Genoma Hum. 2014 Jul-Dec(41):63-87.
8
COVID-19 Tests the Limits of Biodiversity Laws in a Health Crisis: Rethinking "Country of Origin" for Virus Access and Benefit-sharing.新冠疫情大流行对卫生危机中的生物多样性法律提出了挑战:重新思考病毒获取和惠益分享的“起源国”。
J Law Med. 2021 Mar;28(3):684-706.
9
Who Are Indigenous and Local Communities and What Is Traditional Knowledge for Virus Access and Benefit-sharing? A Textual Analysis of the Convention on Biological Diversity and Its Nagoya Protocol.谁是土著和地方社区,关于病毒获取与惠益分享的传统知识是什么?对《生物多样性公约》及其《名古屋议定书》的文本分析
J Law Med. 2018 Apr;25(3):707-726.
10
Multi-Criteria Analysis of Startup Investment Alternatives Using the Hierarchy Method.使用层次分析法对创业投资选择进行多标准分析。
Entropy (Basel). 2023 Apr 27;25(5):723. doi: 10.3390/e25050723.

本文引用的文献

1
Balanced Options for Access and Benefit-Sharing: Stakeholder Insights on Provider Country Legislation.获取与惠益分享的平衡选项:利益相关者对提供国立法的见解
Front Plant Sci. 2019 Oct 1;10:1175. doi: 10.3389/fpls.2019.01175. eCollection 2019.
2
Open Access DNA, RNA and Amino Acid Sequences: The Consequences and Solutions for the International Regulation of Access and Benefit Sharing.开放获取的DNA、RNA和氨基酸序列:获取与惠益分享国际监管的后果与解决方案
J Law Med. 2016;24(1):96-118.
3
Fast Science and Sluggish Policy: The Herculean Task of Regulating Biodiscovery.
快速发展的科学与滞后的政策:监管生物发现的艰巨任务。
Trends Biotechnol. 2018 Jan;36(1):1-3. doi: 10.1016/j.tibtech.2017.09.002. Epub 2017 Sep 27.
4
Microbiological Research Under the Nagoya Protocol: Facts and Fiction.《名古屋议定书下的微生物学研究:事实与虚构》。
Trends Microbiol. 2017 Feb;25(2):85-88. doi: 10.1016/j.tim.2016.11.001. Epub 2016 Nov 22.
5
Sharing the benefits of biodiversity: a new international protocol and its implications for research and development.分享生物多样性的惠益:一项新的国际议定书及其对研究与开发的影响。
Planta Med. 2011 Jul;77(11):1221-7. doi: 10.1055/s-0031-1279978. Epub 2011 Jun 14.